tirzepatide drug shortage list Shortages improve for Lilly's GLP-1 weight loss drugs, bumping sales forecast by $3bn FDA declares shortage over for

The safety data available derive from Phase 2 clinical trials (Jastreboff et al., NEJM, 2023), which, whilst informative, represent a relatively limited population and duration of follow-up compared to post-marketing surveillance

The strongest evidence right now is in knee osteoarthritis (the STEP-9 trial) and rheumatoid arthritis (the UCLA cohort), with rapidly growing data in psoriatic arthritis and lupus

Native human amylin is unusable as a drug because it aggregates into insoluble fibrils

Mistake 2: loading creatine during tirzepatide dose escalation Dose escalation is when tirzepatide GI side effects are worst

Standard insulin syringes have minimal dead space (0.5-2 units)

doi: 10.1016/j.tplants.2012.03.004